Fisetin to Reduce Senescence and Mobility Impairment in PAD

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

June 30, 2027

Conditions
Peripheral Arterial DiseaseAgingPeripheral Vascular DiseasesWalking, DifficultyClaudication
Interventions
DRUG

Fisetin

Fisetin is a flavanol, present in strawberries, apples, and persimmons, that destroys senescent cells (i.e. a senolytic therapy). Of three senolytic therapies being tested in clinical trials, fisetin has the best safety profile.

DRUG

Placebo

The placebo will be matched to the Fisetin intervention

Trial Locations (1)

60611-3008

RECRUITING

Northwestern University Feinberg School of Medicine, Chicago

All Listed Sponsors
lead

Northwestern University

OTHER